| Title |
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, December 2014
|
| DOI | 10.1007/s00262-014-1642-8 |
| Pubmed ID | |
| Authors |
Sofie Wilgenhof, Jurgen Corthals, An M. T. Van Nuffel, Daphné Benteyn, Carlo Heirman, Aude Bonehill, Kris Thielemans, Bart Neyns |
| Abstract |
Melanoma patients with a high risk of recurrence may benefit from immunotherapy with mRNA-electroporated autologous monocyte-derived dendritic cells (DCs). Further benefit may be found in combining DC-therapy with interferon alfa-2b. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 20% |
| Unknown | 4 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 82 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 17% |
| Researcher | 13 | 16% |
| Student > Master | 13 | 16% |
| Other | 8 | 10% |
| Student > Doctoral Student | 7 | 9% |
| Other | 12 | 15% |
| Unknown | 15 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 28% |
| Agricultural and Biological Sciences | 18 | 22% |
| Biochemistry, Genetics and Molecular Biology | 9 | 11% |
| Immunology and Microbiology | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 3 | 4% |
| Unknown | 19 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2021.
All research outputs
#3,879,218
of 22,775,504 outputs
Outputs from Cancer Immunology, Immunotherapy
#393
of 2,881 outputs
Outputs of similar age
#53,861
of 352,738 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#3
of 25 outputs
Altmetric has tracked 22,775,504 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,881 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,738 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.